Bayer appoints new Chairman & Managing Director in Australia & New Zealand

Ashraf Al-Ouf and Joerg Ellmanns
Ashraf Al-Ouf, new the Chairman and Managing Director of the Bayer Group in Australia and New Zealand (ANZ), succeeds Joerg Ellmanns who will depart Bayer after more than 35 years of service with the organisation.

 

Sydney, 16 September 2022 – Bayer is pleased to announce Ashraf Al-Ouf as the Chairman and Managing Director of the Bayer Group in Australia and New Zealand (ANZ). He succeeds Joerg Ellmanns who will depart Bayer after more than 35 years of service with the organisation.

 

Mr Al-Ouf will step into his new position from 1 November. He will continue to oversee the Pharmaceuticals division of Bayer in ANZ, as well as lead all of Bayer’s corporate operations in ANZ.
 

Bayer’s Head of Human Resources in ANZ, Karina Raeburn, said the organisation sincerely thanks Joerg for his innumerable contributions to our people and operations across ANZ over the past 14 years.

 

“We are pleased to confirm Ashraf as Joerg’s successor,” Ms Raeburn said. “A passionate and effective leader, Ashraf brings more than 20 years’ experience with Bayer across Asia-Pacific, Germany and the Middle East.”

 

Originally from Jordan, Mr Al-Ouf commenced his current role in ANZ in July 2019 and, prior to that, held various positions in Asia Pacific, including VP General Manager Business Unit Cardiovascular in Japan and President Director of the Bayer Group in Indonesia. He is also a member of the Medicines Australia Board. 

 

Mr Al-Ouf said he is thrilled to take on this position as Bayer continues to advance its vision of health for all, hunger for none.

 

“As a life science company, we proudly specialise in advancing health and agriculture. I am steadfast in my focus on making continual improvements to the lives of Australians and New Zealanders,” he said.

 

“Our role in science, health and agriculture has never been more important, particularly in light of global food shortages and the ongoing impacts to healthcare as a result of the pandemic.”

 

Mr Ellmanns’ career with Bayer spans more than 35 years across multiple markets including Australia, Benelux, South Africa, the US and Germany.  Bayer ANZ has greatly benefited from his expertise since first joining the local organisation in 2008. He remains a dynamic and inspiring leader who has invested heavily in people to develop Bayer in ANZ as the purpose-driven organisation it is today, dedicated to helping people and the planet to thrive. 

 

Mr Ellmanns said it had been an honour to work for Bayer over the past three decades and to lead the ANZ team in its commitment to improving the lives of patients, farmers and consumers across the two countries.

 

“Thank you to all of my colleagues at Bayer ANZ and beyond, and to all of our communities and partners for their support over the years. “I wish Ashraf every success in his new role,” he concluded.

 

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care, nutrition and agriculture. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. The company has operated in Australia since 1925 and has a long-term commitment to the health and nutrition of all Australians. Locally, Bayer currently employs almost 900 people across the country and is dedicated to servicing the needs of rural and remote communities. Bayer embraces and encourages its employees’ unique identities and advances a culture of inclusion and diversity across gender, LGBTQI+, generations, disability and race. For more information, go to www.bayer.com.au


Contact:
Melanie Roukoz, phone +61 458 524422
Email: melanie.roukoz@bayer.com

 

Forward-Looking Statements 
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.